ASX:PYCBiotechs
PYC Therapeutics H1 2026 Losses Highlight Ongoing Investment And Test Bullish Profitability Narrative
PYC Therapeutics (ASX:PYC) has reported its H1 2026 numbers with trailing twelve month revenue of A$21.8 million and a basic EPS loss of A$0.085, indicating that the business is still investing heavily to progress its pipeline. Over recent reporting periods, revenue has moved from A$13.2 million in H2 2024 to A$11.8 million in H1 2025 and A$11.7 million in H2 2025, while basic EPS losses have shifted from A$0.055 in H2 2024 to A$0.0548 in H1 2025 and A$0.046 in H2 2025. This gives investors a...